IMPACT Partners Pharmanovia to Expand Senaparib Across 66 Countries
IMPACT Therapeutics has signed an exclusive licensing agreement with global specialty pharmaceutical company Pharmanovia to expand the reach of its ovarian cancer treatment, senaparib, across Europe, the Middle East and North Africa (MENA), Australia and New Zealand. The partnership marks IMPACT’s first major commercialization agreement outside China and could generate up to €423.5 million in payments and royalties for the company.
Under the agreement, Pharmanovia will receive exclusive rights to manufacture, develop and commercialize senaparib for maintenance monotherapy in adults with advanced epithelial high-grade ovarian, fallopian tube and primary peritoneal cancer across 66 countries. The territories covered include all 27 European Union member states, the United Kingdom, Norway, Iceland, Switzerland, Liechtenstein, Australia, New Zealand and several countries in the Middle East and North Africa.
The deal is designed to accelerate patient access to senaparib in international markets while strengthening IMPACT’s position as a global oncology company.
Financially, the agreement provides IMPACT with an upfront payment, near-term regulatory milestone payments and additional commercial milestone payments tied to sales performance. If all milestones are achieved, the company could receive up to €423.5 million. In addition, IMPACT will be eligible for tiered royalties reaching the mid-twenties percentage range on future net product sales.
The agreement comes as senaparib moves closer to regulatory approval in Europe. The European Medicines Agency (EMA) formally accepted the Marketing Authorisation Application (MAA) for the drug in August 2025. The application seeks approval for senaparib as a first-line maintenance treatment for adults with advanced ovarian cancer, with a regulatory decision expected during the second half of 2026.
If approved, the medicine could provide a new maintenance treatment option for patients diagnosed with advanced epithelial high-grade ovarian cancer, as well as cancers of the fallopian tubes and primary peritoneum. Maintenance therapies are used after initial treatment to help delay disease progression and improve long-term outcomes.
The partnership is a significant milestone for IMPACT Therapeutics, which has focused primarily on the Chinese market since its establishment. By partnering with Pharmanovia, the company aims to introduce its oncology innovation to a broader international patient population while relying on an experienced commercial partner with an established presence across multiple regions.
According to IMPACT, Pharmanovia’s regulatory expertise, commercial infrastructure and experience in specialty medicines are expected to help accelerate the launch of senaparib once regulatory approvals are secured. The collaboration is intended to ensure that eligible patients gain faster access to the treatment following approval.
The company also believes the partnership will strengthen global recognition of both senaparib and the IMPACT brand, supporting its long-term international growth strategy. Beyond expanding geographical coverage, the agreement represents an important step in transforming IMPACT from a domestic biotechnology company into a global oncology player with commercial operations extending well beyond China.
For Pharmanovia, the licensing agreement further expands its oncology portfolio and reinforces its strategy of partnering with biotechnology companies and larger pharmaceutical firms to commercialize innovative specialty medicines in underserved markets.
The companies plan to work closely together throughout the regulatory review process and subsequent commercialization activities across the licensed territories. Their collaboration will include manufacturing, regulatory development and market launch preparations to ensure senaparib is available as quickly as possible following approval.
With the agreement extending senaparib’s potential availability to 66 countries, IMPACT Therapeutics is positioning the therapy for a much broader global rollout. If regulatory approval is granted as anticipated in Europe next year, the partnership could significantly increase patient access to the treatment while creating substantial long-term commercial opportunities for both companies.